We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+10.9%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$3.81B
AUM Growth
+$244M
Cap. Flow
-$21.2M
Cap. Flow %
-0.56%
Top 10 Hldgs %
49.66%
Holding
160
New
23
Increased
21
Reduced
32
Closed
35

Top Buys

Rank Stock Value
1
VRCA icon
Verrica Pharmaceuticals
VRCA
+$66.8M
2
MGTX icon
MeiraGTx Holdings
MGTX
+$63.1M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$56.2M
4
ISRG icon
Intuitive Surgical
ISRG
+$41.2M
5
KDMN
Kadmon Holdings, Inc.
KDMN
+$31.2M

Top Sells

Rank Stock Value
1
ABMD
Abiomed Inc
ABMD
+$107M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$47.9M
3
AVXS
AveXis, Inc. Common Stock
AVXS
+$34.2M
4
ANAB icon
AnaptysBio
ANAB
+$24.7M
5
AGIO icon
Agios Pharmaceuticals
AGIO
+$20.4M

Sector Composition

Rank Sector Weight
1 Healthcare 92.91%
2 Industrials 0.65%
3 Consumer Discretionary 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HUM icon
26
Humana
HUM
$43.9B
$44.1M 1.16%
148,218
+87,500
+144% +$25.6M
CTMX icon
27
CytomX Therapeutics
CTMX
$690M
$43.9M 1.15%
1,921,715
-287,097
-13% -$7.33M
ARGX icon
28
argenx
ARGX
$55.2B
$43.9M 1.15%
529,560
-7,801
-1% -$697K
DBVT
29
DBV Technologies
DBVT
$813M
$40.7M 1.07%
210,820
+1,470
+0.7% +$331K
XNCR icon
30
Xencor
XNCR
$1.45B
$39.5M 1.04%
1,068,095
-250,000
-19% -$8.62M
CBAY
31
DELISTED
Cymabay Therapeutics
CBAY
$36.8M 0.97%
2,742,821
-60,000
-2% -$751K
ARNA
32
DELISTED
Arena Pharmaceuticals Inc
ARNA
$36.7M 0.96%
841,978
+670,000
+390% +$28.8M
MRTX
33
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$35.2M 0.92%
713,191
+684,100
+2,352% +$25.8M
ADMA icon
34
ADMA Biologics
ADMA
$2.02B
$29.4M 0.77%
6,521,102
+2,700,000
+71% +$13.5M
ADMS
35
DELISTED
Adamas Pharmaceuticals
ADMS
$28M 0.73%
1,084,159
+454,159
+72% +$12.6M
PBYI icon
36
Puma Biotechnology
PBYI
$398M
$27.7M 0.73%
564,579
+122,400
+28% +$7.09M
VBIV
37
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$26.6M 0.7%
322,195
– –
ECYT
38
DELISTED
Endocyte, Inc. Common Stock
ECYT
$26.5M 0.7%
1,921,700
-280,000
-13% -$3.32M
BOLD
39
DELISTED
Audentes Therapeutics, Inc
BOLD
$25.2M 0.66%
660,406
-95,809
-13% -$3.55M
RYTM icon
40
Rhythm Pharmaceuticals
RYTM
$7.31B
$25M 0.66%
800,686
+208,400
+35% +$5.7M
IRTC icon
41
iRhythm Holdings
IRTC
$4.02B
$25M 0.66%
308,006
-111,700
-27% -$7.81M
ALDX icon
42
Aldeyra Therapeutics
ALDX
$97.1M
$24.5M 0.64%
3,085,458
– –
ATHN
43
DELISTED
Athenahealth, Inc.
ATHN
$23.9M 0.63%
+150,000
New +$22.2M
ONCT
44
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$23M 0.6%
+10,725
New +$27.2M
AKBA icon
45
Akebia Therapeutics
AKBA
$338M
$22.1M 0.58%
2,215,400
-247,000
-10% -$2.47M
NEPT
46
DELISTED
Neptune Wellness Solutions Inc. Ordinary Shares
NEPT
$20.4M 0.53%
6,124
– –
MOTS
47
DELISTED
Motus GI Holdings, Inc. Common Stock
MOTS
$20.2M 0.53%
9,368
– –
ZYME icon
48
Zymeworks
ZYME
$1.62B
$15.9M 0.42%
1,123,890
+430,000
+62% +$6.66M
ABMD
49
DELISTED
Abiomed Inc
ABMD
$15M 0.39%
36,646
-295,803
-89% -$107M
NVTA
50
DELISTED
Invitae Corporation
NVTA
$14.9M 0.39%
2,021,100
+170,000
+9% +$1.13M
1
2
3 4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q2 2018 Portfolio in Review

As of Q2 2018, Perceptive Advisors held 160 positions worth $3.81B, up 6.8% from $3.57B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Perceptive Advisors's Q2 2018 filing shows 23 new, 21 increased, 32 reduced and 35 closed positions. Its largest new stake was Verrica Pharmaceuticals: 341,041 shares worth $67.3M. The largest sale was Abiomed Inc, an estimated $107M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 96% a quarter earlier, followed by Industrials and Consumer Discretionary.

  • Perceptive Advisors's largest Q2 2018 buy was Verrica Pharmaceuticals: 341,041 shares worth $67.3M.
  • Perceptive Advisors added most to Alnylam Pharmaceuticals in Q2 2018, an estimated $56.2M increase.
  • Perceptive Advisors's biggest Q2 2018 reduction was Abiomed Inc, cutting an estimated $107M.
  • Perceptive Advisors fully exited AveXis, Inc. Common Stock in Q2 2018, selling an estimated $34.2M.
  • Perceptive Advisors's ten largest holdings make up 50% of its $3.81B portfolio in Q2 2018.
  • Perceptive Advisors opened 23 new positions and closed 35 in Q2 2018.
  • Perceptive Advisors's portfolio value rose 6.8% quarter-over-quarter to $3.81B.

Based on Perceptive Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.